These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 11992038)

  • 1. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
    Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
    J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
    Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
    J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
    Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
    Elife; 2024 Apr; 13():. PubMed ID: 38656229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
    Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
    J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.
    Higano C; Shields A; Wood N; Brown J; Tangen C
    Urology; 2004 Dec; 64(6):1182-6. PubMed ID: 15596194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T; Campbell J; Bryant C; Lynch W
    Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of androgen suppression on bone mineral density in patients with prostate cancer.
    Chernichenko OA; Sakalo VS; Yakovlev PG; Sakalo AV; Zhylchuk YV; Zsolt A
    Exp Oncol; 2014 Dec; 36(4):276-8. PubMed ID: 25537224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
    Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
    J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body composition during androgen deprivation therapy for prostate cancer.
    Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
    J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
    Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
    Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.